Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             122 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A cost-effectiveness analysis of Herceptin® (trastuzumab) in combination with Paclitaxel as a first line treatment for HER2 positive (3+) Metastatic Breast Cancer (MBC) patients in the UK Ratcliffe, A.
 2001
 37 S5 p. 4-
1 p.
 artikel
2 Adjuvant radiotherapy for breast cancer - do we need new techniques? Appel, W.
 2001
 37 S5 p. 36-37
2 p.
 artikel
3 Age is not an independent prognostic factor Blamey, R.W.
 2001
 37 S5 p. 42-
1 p.
 artikel
4 Angiogenesis in ductal carcinoma in situ (DCIS) of the breast Teo, N.B.
 2001
 37 S5 p. 36-
1 p.
 artikel
5 A novel grading system to assess pathological response and predict survival in patients receiving primary chemotherapy for breast cancer Ogston, K.N.
 2001
 37 S5 p. 27-
1 p.
 artikel
6 A review of aromatase inhibitors used for neoadjuvant endocrine therapy Dixon, J.M.
 2001
 37 S5 p. 6-
1 p.
 artikel
7 A single institutional experience with sentinel node biopsy in 400 breast cancer patients Tanis, P.J.
 2001
 37 S5 p. 23-
1 p.
 artikel
8 Author index 2001
 37 S5 p. 45-48
4 p.
 artikel
9 Blue and hot hits the spot- or does it not? comparability of a four node sample to sentinel node biopsy Rampaul, R.S.
 2001
 37 S5 p. 23-24
2 p.
 artikel
10 Breast cancer in the elderly: Surgery improves survival. The results of a cancer research campaign trial Bates, T.
 2001
 37 S5 p. 7-
1 p.
 artikel
11 Breast cancer patients use of a touch screen in the day treatment area to record toxicity, health state and quality of life - A 12 month experience Leonard, R.C.F.
 2001
 37 S5 p. 27-
1 p.
 artikel
12 Can ultrasound improve the accuracy of delivery of electron boost treatment following breast conserving surgery? Haba, Y.
 2001
 37 S5 p. 38-
1 p.
 artikel
13 Capecitabine named patient program for patients with advanced breast cancer: The UK experience Leonard, R.C.F.
 2001
 37 S5 p. 28-
1 p.
 artikel
14 C-erbB-2 in lymph node negative breast cancer: Prognostic significance in univariate and multivariate analyses Rampaul, R.S.
 2001
 37 S5 p. 35-36
2 p.
 artikel
15 CerbB2 oncoprotein expression is increased in breast cancer bone metastases Linforth, R.A.
 2001
 37 S5 p. 11-
1 p.
 artikel
16 Changes in proliferation in breast cancer with tamoxifen and correlation with tumour response Iqbal, S.
 2001
 37 S5 p. 21-
1 p.
 artikel
17 Changing patterns of surgery: The trent breast screening program 1997-2000 Caldon, L.J.M.
 2001
 37 S5 p. 33-
1 p.
 artikel
18 Chromosomal alterations associated with transformation of a tamoxifen-sensitive cell line into its drug resistant clone Achuthan, R.
 2001
 37 S5 p. 29-30
2 p.
 artikel
19 Coexpression of EGFr, HER2, HER3 and HER4 in primary human breast carcinoma Witton, C.J.
 2001
 37 S5 p. 21-22
2 p.
 artikel
20 Combined use of goserelin (zoladex) and anastrozole (arimidex) as second-line endocrine therapy in premenopausal women with advanced breast cancer — a study of its clinical and endocrine effects Cheung, K.L.
 2001
 37 S5 p. 8-
1 p.
 artikel
21 Comparative genomic hybridisation analysis of 40 breast cancers with long term patient survival data Hislop, R.G.
 2001
 37 S5 p. 42-
1 p.
 artikel
22 Comparison of margin status with Van Nuys index to predict recurrence of ductal carcinoma in situ after breast conserving surgery Boland, G.
 2001
 37 S5 p. 15-
1 p.
 artikel
23 Comparison of oestrogen receptor α and β mRNA and protein in malignant and non-malignant breast Udokang, K.
 2001
 37 S5 p. 30-
1 p.
 artikel
24 Concordant loss of heterozygosity in tumour pairs of breast cancer families as a predictor of germline mutations Cid, J.A.
 2001
 37 S5 p. 10-
1 p.
 artikel
25 Core biopsy versus fine needle aspiration cytology (FNAC) for palpable breast cancers. Is image guidance necessary? Agarwal, T.
 2001
 37 S5 p. 12-
1 p.
 artikel
26 Correlation between immunohistochemical and fish analysis for HER-2 in 441 breast carcinomas from multiple hospitals Dowsett, M.
 2001
 37 S5 p. 3-4
2 p.
 artikel
27 Correlation of Immunohistochemistry (IHC) and gene microarray analysis of breast biopsies from a preoperative endocrine therapy trial Coop, A.
 2001
 37 S5 p. 9-10
2 p.
 artikel
28 Cosmesis and satisfaction after breast conserving surgery (BCS) correlates with the percentage of breast volume lost Cochrane, R.A.
 2001
 37 S5 p. 31-32
2 p.
 artikel
29 Delay to fixation of invasive breast carcinoma: Effect on mitotic count, MIB1, ER and P53 expression Brearley, N.
 2001
 37 S5 p. 10-
1 p.
 artikel
30 Detection of isolated tumor cells in bone marrow in early stage breast cancer. Final laboratory results from the oslo study Kåresen, R.
 2001
 37 S5 p. 42-43
2 p.
 artikel
31 Discussion paper — sentinel node biopsy: Hope or hype? Blamey, R.W.
 2001
 37 S5 p. 24-25
2 p.
 artikel
32 Does axillary node sampling in addition to sentinel node biopsy provide useful staging information in patients with breast cancer? Hoar, F.J.
 2001
 37 S5 p. 23-
1 p.
 artikel
33 Does radical surgery to the axilla give a survival advantage in more severe breast cancer? Sinha, P.
 2001
 37 S5 p. 17-
1 p.
 artikel
34 Efficacy of tamoxifen (TAM) following Anastrozole (AN) as first-line treatment for Advanced Breast Cancer (ABC) in Postmenopausal (PM) Patients (PTS) Thürlimann, B.
 2001
 37 S5 p. 5-
1 p.
 artikel
35 Epidermal Growth Factor Receptor (EGFR) expression: Prognostic value in breast cancer patients with long-term follow-up Rampaul, R.S.
 2001
 37 S5 p. 12-
1 p.
 artikel
36 Evaluation of long term recurrence rate following breast conserving surgery after neoadjuvant endocrine therapy Dixon, J.M.
 2001
 37 S5 p. 7-
1 p.
 artikel
37 Expression of estrogen receptor β — comparison between invasive lobular and ductal cancers of the breast Munot, K.
 2001
 37 S5 p. 41-
1 p.
 artikel
38 Factors affecting cosmetic outcome after breast conserving surgery Stevenson, J.
 2001
 37 S5 p. 31-
1 p.
 artikel
39 Factors influencing the detection rate and the false negative rate in sentinel node biopsy in breast cancer Frisell, J.
 2001
 37 S5 p. 24-
1 p.
 artikel
40 Factors underlying the improvement in mortality from breast cancer Blamey, R.W.
 2001
 37 S5 p. 6-
1 p.
 artikel
41 Failure to identify sentinel nodes at operation for screen detrected breast cancers Gill, P.G.
 2001
 37 S5 p. 19-20
2 p.
 artikel
42 Frequency of breast and other cancers among relatives of male breast cancer patients Young, I.E.
 2001
 37 S5 p. 39-
1 p.
 artikel
43 Heat shock protein 27 as a marker of malignant potential in normal, benign and invasive breast lesions O'Neill, P.A.
 2001
 37 S5 p. 10-
1 p.
 artikel
44 HER-2 status in locally advanced breast cancer Doran, C.
 2001
 37 S5 p. 11-
1 p.
 artikel
45 Higher expression of vascular endothelial growth factor (VEGF) correlates with mutant p53, oestrogen receptor (ER) negativity, and shorter survival times in primary breast cancer Linderholm, B.
 2001
 37 S5 p. 36-
1 p.
 artikel
46 Hormone receptor status in primary breast cancer — time for a consensus? Wishart, G.C.
 2001
 37 S5 p. 1-
1 p.
 artikel
47 Hypersensitive K303R oestrogen receptor variant not found in ductal carcinoma in situ Davies, M.P.A.
 2001
 37 S5 p. 29-
1 p.
 artikel
48 Hypothesis P53 mutation as basis for effect of paclitaxel-containing therapy on ER-negative tumours and of tamoxifen in obfuscating this in ER-positive in CALGB9344 Poole, C.J.
 2001
 37 S5 p. 1-2
2 p.
 artikel
49 ICI 182,780 (‘FASLODEX’) is at least as effective as anatrozole (Arimidex™) in post-menopausal women with advanced breast cancer progressing on prior endocrine treatment Howell, A.
 2001
 37 S5 p. 9-
1 p.
 artikel
50 ICI 182,780 (‘FASLODEX’) 250 mg monthly Intramuscular (I.M.) injection shows consistent Pharmacokinetic (PK) profiles when given as either 1 × 5 ml or 2 × 2.5 ml injections in postmenopausal women with Advanced Breast Cancer (ABC) Robertson, J.F.R.
 2001
 37 S5 p. 8-9
2 p.
 artikel
51 Immediate breast reconstruction: The factors affecting cosmesis and patient satisfaction Daltrey, I.R.
 2001
 37 S5 p. 32-
1 p.
 artikel
52 Immediate breast reconstruction using the latissimus dorsi myocutaneous flap (LDF): Long term results at 15 years plus Tan, S.-Y.
 2001
 37 S5 p. 22-23
2 p.
 artikel
53 Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: A randomised controlled trial Ogston, K.N.
 2001
 37 S5 p. 26-
1 p.
 artikel
54 Incidence and prognosis in early-onset breast cancer Sundquist, M.
 2001
 37 S5 p. 41-42
2 p.
 artikel
55 Incidence of lymph node metastases in infiltrating breast cancers of less than 10 mm Sharp, C.M.
 2001
 37 S5 p. 34-
1 p.
 artikel
56 Intra-operative frozen section reliably predicts sentinel node status in patients with breast cancer MacLean, M.E.
 2001
 37 S5 p. 18-
1 p.
 artikel
57 Intraoperative radiotherapy after breast conserving therapy — an alternative to conventional postoperative boost? Reitsamer, R.
 2001
 37 S5 p. 37-
1 p.
 artikel
58 Invasive carcinomas in cases judged to be ductal carcinoma in situ at triple assessment Wahedna, Y.
 2001
 37 S5 p. 14-
1 p.
 artikel
59 Invasive lobular carcinoma: Is it still difficult to diagnose? Kurup, V.
 2001
 37 S5 p. 14-
1 p.
 artikel
60 Is hormone replacement (HRT) — related breast cancer more favourable? A case-control study Khan, H.
 2001
 37 S5 p. 35-
1 p.
 artikel
61 Is the MCF-7 breast cancer cell line of value in research? Bahia, H.
 2001
 37 S5 p. 11-
1 p.
 artikel
62 Letrozole (femara) is a more effective inhibitor of estrogen activity than tamoxifen: Evidence from a randomized phase III trial of 4 months preoperative endocrine therapy for postmenopausal women with primary invasive breast cancer Ellis, M.J.
 2001
 37 S5 p. 8-
1 p.
 artikel
63 Lipsome-encapsulated doxorubicin (MYOCET) and cyclophosphamide is superior to epirubicin and cyclophosphamide in first-line therapy of metastatic breast cancer Chan, S.
 2001
 37 S5 p. 28-
1 p.
 artikel
64 Local recurrence following neoadjuvant chemotherapy in patients with large and locally advanced breast cancer McIntosh, S.A.
 2001
 37 S5 p. 26-
1 p.
 artikel
65 Longterm locoregional control and morbidity after postmastectomy radiotherapy (PMRT) Greenhouse, A.
 2001
 37 S5 p. 16-
1 p.
 artikel
66 Lymphoedema rate following treatment for primary breast cancer Mullinger, K.
 2001
 37 S5 p. 14-15
2 p.
 artikel
67 Minimally invasive breast surgery: Experience with the mammotome Schuijtvlot, M.
 2001
 37 S5 p. 25-
1 p.
 artikel
68 Morphological assessment of heat shock protein 27 and oestrogen receptor alpha, potential markers of breast cancer risk Shabaan, A.M.
 2001
 37 S5 p. 21-
1 p.
 artikel
69 MRI enables accurate diagnosis and single stage surgical resection of invasive lobular breast cancers Munot, K.
 2001
 37 S5 p. 33-
1 p.
 artikel
70 Occult axillary lymph node metastases are of no prognostic significance breast cancer Millis, R.R.
 2001
 37 S5 p. 24-
1 p.
 artikel
71 Oestrogen withdrawal reduces epithelial cell proliferation in oestrogen receptor (ER) positive but not negative ductal carcinoma in-situ (DCIS) Boland, G.P.
 2001
 37 S5 p. 29-
1 p.
 artikel
72 Ovarian suppression plus tamoxifen (TAM) versus chemotherapy (CT) in patients with early breast cancer: Results of a meta-analysis of three adjuvant trials Boccardo, F.
 2001
 37 S5 p. 40-
1 p.
 artikel
73 Patients' perceptions of their prognosis and their expectations of the benefit of adjuvant chemotherapy in early breast cancer Innes, H.E.
 2001
 37 S5 p. 27-28
2 p.
 artikel
74 Patients who are node negative on axillary node sampling: Do they recur because of occult lymph node metastases missed by the pathologist? Murray, K.L.
 2001
 37 S5 p. 20-
1 p.
 artikel
75 Percutaneous minimally invasive stereotactic primary radiotherapy: A novel approach for breast cancer in elderly women Vaidya, J.S.
 2001
 37 S5 p. 37-38
2 p.
 artikel
76 Phase III trial of Anastrozole (AN) vs Tamoxifen (TAM) in Postmenopausal (PM) Patients (PTS) with hormone-dependent Advanced Breast Cancer (ABC) Milla-Santos, A.
 2001
 37 S5 p. 4-
1 p.
 artikel
77 Predicting sentinel node involvement: Manchester experince Elangovan, A.E.
 2001
 37 S5 p. 19-
1 p.
 artikel
78 Prospective randomised study comparing radio-guided surgery (ROLL) to wire-guidance for occult breast lesions localisation Rampaul, R.S.
 2001
 37 S5 p. 2-3
2 p.
 artikel
79 Randomised study of axillary clearance versus four node sampling Lambah, A.
 2001
 37 S5 p. 2-
1 p.
 artikel
80 Randomized controlled trial comparing 14G core biopsy with minimally invasive breast biopsy (MIBB) in pre-operative diagnosis of mammographically detected breast lesions Hurley, E.
 2001
 37 S5 p. 25-
1 p.
 artikel
81 Recurrence and outcome after treatment of ductal carcinoma in situ Jenkins, J.
 2001
 37 S5 p. 15-
1 p.
 artikel
82 Reliability of stereo-tactic core biopsy diagnosed ductal carcinoma in-situ (DCIS) for screen detected microcalfication Boland, G.P.
 2001
 37 S5 p. 13-14
2 p.
 artikel
83 Role of ultrasound scan in women complaining of a breast lump but with normal clinical examination Cid, J.A.
 2001
 37 S5 p. 13-
1 p.
 artikel
84 Routine hospital follow up of breast cancer — time for a new approach? Donnelly, J.
 2001
 37 S5 p. 33-34
2 p.
 artikel
85 Scintimammography: Does size matter? Buscombe, J.R.
 2001
 37 S5 p. 3-
1 p.
 artikel
86 Sentinel lymph node biopsy in breast cancer — is lymphoscinitigraphy really necessary? Upponi, S.S.
 2001
 37 S5 p. 18-
1 p.
 artikel
87 Sentinel node — a new injection technique Guldvog, I.
 2001
 37 S5 p. 17-
1 p.
 artikel
88 Sentinel node biopsy in screen detected impalpable breast cancer using peri-areolar radionuclide injection Seth, S.
 2001
 37 S5 p. 17-
1 p.
 artikel
89 Sentinel node (SN) biopsy can safely replace axillary node sampling for staging early breast cancer Agarwal, T.
 2001
 37 S5 p. 20-
1 p.
 artikel
90 Serial monitoring of serum HER-2/neu in women with metastatic breast cancer Neumann, R.
 2001
 37 S5 p. 38-
1 p.
 artikel
91 Serum and tissue CerbB-2 antigen levels predicts outcome and response to hormonal therapy of bone metastatic breast cancer Elangovan, A.E.
 2001
 37 S5 p. 30-31
2 p.
 artikel
92 Service implications of introducing sentinel node biopsy: Extrapolations from the first 100 patients randomised to the ALMANAC trial Rose, K.
 2001
 37 S5 p. 20-21
2 p.
 artikel
93 Should we follow breast cancer patients Kokan, J.
 2001
 37 S5 p. 34-
1 p.
 artikel
94 Studies with iressa, a novel EGF receptor tyrosine kinase inhibitor on breast cancer cells and in situ cancer “in vivo” Chan, K.C.
 2001
 37 S5 p. 16-
1 p.
 artikel
95 Surgeon directed ultrasound guided core biopsies in the breast — a prospective study Donaldson, L.A.
 2001
 37 S5 p. 12-
1 p.
 artikel
96 Surgeon workload and survival of breast cancer patients Stefoski-Mikeljevic, J.
 2001
 37 S5 p. 6-
1 p.
 artikel
97 Surgical management of the axilla following primary chemotherapy for T3 M0 breast cancer Hospital, A.E.
 2001
 37 S5 p. 26-27
2 p.
 artikel
98 Survival after ductal carcinoma in situ (DCIS) Wahedna, Y.
 2001
 37 S5 p. 16-
1 p.
 artikel
99 Symptomatic breast cancer patients in the UK rarely present with tumours 1 cm or less: The implications for medico-legal claims of delay in diagnosis Diggin, P.
 2001
 37 S5 p. 13-
1 p.
 artikel
100 Tables of anticipated benefit from adjuvant therapy for the individual Blamey, R.W.
 2001
 37 S5 p. 5-6
2 p.
 artikel
101 Tamoxifen and arimidex do not inhibit angiogenesis in vitro Tormey, S.
 2001
 37 S5 p. 30-
1 p.
 artikel
102 Tamoxifen beyond five years — patient's equipoise Ferguson, M.J.
 2001
 37 S5 p. 7-
1 p.
 artikel
103 Targ eted i ntra-operative radio t herapy (targit) for breast cancer — a randomised trial Vaidya, J.S.
 2001
 37 S5 p. 37-
1 p.
 artikel
104 The ALMANAC trial — early results from the audit phase Clarke, D.
 2001
 37 S5 p. 18-19
2 p.
 artikel
105 The anti-tumour effects of conjugated linoleic acid in breast cancer are mediated both by P-53 dependent and independent apoptotic pathways Majumder, B.
 2001
 37 S5 p. 28-29
2 p.
 artikel
106 The BASO II trial of adjuvant radiotherapy. V. None and tamoxifen. V. None in small, node negative, grade I tumours Blamey, R.W.
 2001
 37 S5 p. 2-
1 p.
 artikel
107 The clinical significance of internal mammary sentinel nodes in primary breast cancer Kollias, J.
 2001
 37 S5 p. 19-
1 p.
 artikel
108 The development & detection of local recurrence following breast conservation therapy (BCT) Caldwell, S.
 2001
 37 S5 p. 32-
1 p.
 artikel
109 The effect of anastrozole (Arimidex™) on serum lipids — a randomized comparison of Anastrozole (AN) vs Tamoxifen (TAM) in Postmenopausal women with Advanced Breast Cancer Dewar, J.
 2001
 37 S5 p. 5-
1 p.
 artikel
110 The effect of family history on prognosis in breast cancer Ahmed, L.
 2001
 37 S5 p. 35-
1 p.
 artikel
111 The history of breast cysts is not associated with the diagnosis of breast cancer Chetty, U.
 2001
 37 S5 p. 39-
1 p.
 artikel
112 The influence of oestradiol on integrin (1 expression and function in breast cancer and the effects of long-term oestrogen deprivation Pogson, C.J.
 2001
 37 S5 p. 31-
1 p.
 artikel
113 The prognostic value of contralateral, metachronous, and bilateral, synchronous breast cancer in breast cancer patients Jobsen, J.J.
 2001
 37 S5 p. 22-
1 p.
 artikel
114 The relationship of oestrogen receptor (ER) status to treatment outcome in breast cancer (BC) therapy Sainsbury, R.
 2001
 37 S5 p. 1-
1 p.
 artikel
115 The role of dynamic imaging in sentinel biopsy in breast cancer Keshtgar, M.R.S.
 2001
 37 S5 p. 17-18
2 p.
 artikel
116 The ZEBRA study: Early benefits in quality of life in goserelin-treated vs CMF-treated pre-/perimenopausal patients with node-positive early breast cancer Olschewski, M.
 2001
 37 S5 p. 40-
1 p.
 artikel
117 The ZEBRA study: Reversibility of bone mineral density of pre-/perimenopausal patients with node-positive early breast cancer after treatment with Zoladex™ Blake, G.M.
 2001
 37 S5 p. 41-
1 p.
 artikel
118 The ZEBRA study: Zoladex™ is as effective as CMF in pre-/perimenopausal patients with oestrogen receptor positive, node-positive early breast cancer Blamey, R.
 2001
 37 S5 p. 39-40
2 p.
 artikel
119 UK Expanded Access Programme (EAP): Herceptin® (trastuzumab) treatment for women with HER2 positive Metastatic Breast Cancer (MBC) Miles, D.
 2001
 37 S5 p. 3-
1 p.
 artikel
120 Use of hormonal replacement therapy (HRT) does not adversely affect survival from screen detected breast cancer Prasad, R.
 2001
 37 S5 p. 34-35
2 p.
 artikel
121 When is a breast lump a lump? How good are general practitioners (GP) in their diagnosis, and how good are Breast Surgeons? Davis, C.
 2001
 37 S5 p. 13-
1 p.
 artikel
122 Wide local excision with 10 mm clearance without radiotherapy for DCIS Rampaul, R.S.
 2001
 37 S5 p. 15-
1 p.
 artikel
                             122 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland